Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aims of the study are as follows:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Calcium alpha-ketoglutarate (Ca-aKG) | Experimental | At the first and second cataract surgery of the participant, a small amount of tissue (eye fluid ~0.1 ml or 1-2 drops) is removed for analysis. Beginning one week (7 days) prior to their second cataract extraction surgery, the patient takes an oral nutritional supplement (calcium alpha-ketoglutarate) 2 times a day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Calcium alpha-ketoglutarate | Drug | Participants took 2 g/day of calcium alpha-ketoglutarate orally, twice daily, for 7 days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean change in aqueous humor aKG level | To evaluate the mean difference in fold-change in aKG levels from baseline to post-supplementation in eye fluid | Baseline and post-supplementation, approximately 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Mean fold-change in metabolic and retinal pathways | To calculate mean fold-change in retinal metabolic and protein pathways from baseline to post-supplementation in eye fluid | Baseline and post-supplementation, approximately 28 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vinit Mahajan, MD, PhD | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Byers Eye Institute | Palo Alto | California | 94303 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17896582 | Background | Filip RS, Pierzynowski SG, Lindegard B, Wernerman J, Haratym-Maj A, Podgurniak M. Alpha-ketoglutarate decreases serum levels of C-terminal cross-linking telopeptide of type I collagen (CTX) in postmenopausal women with osteopenia: six-month study. Int J Vitam Nutr Res. 2007 Mar;77(2):89-97. doi: 10.1024/0300-9831.77.2.89. | |
| 8893139 |
Not provided
Not provided
Age, sex, BMI, Medical history, ocular history
The data will be made available upon study registration with CTgov, and will remain available for at least 5 years.
Results
Not provided
Not provided
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007656 | Ketoglutaric Acids |
| ID | Term |
|---|---|
| D005977 | Glutarates |
| D003998 | Dicarboxylic Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Riedel E, Nundel M, Hampl H. alpha-Ketoglutarate application in hemodialysis patients improves amino acid metabolism. Nephron. 1996;74(2):261-5. doi: 10.1159/000189319. |
| 32028070 | Background | Wert KJ, Velez G, Kanchustambham VL, Shankar V, Evans LP, Sengillo JD, Zare RN, Bassuk AG, Tsang SH, Mahajan VB. Metabolite therapy guided by liquid biopsy proteomics delays retinal neurodegeneration. EBioMedicine. 2020 Feb;52:102636. doi: 10.1016/j.ebiom.2020.102636. Epub 2020 Feb 3. |
| 33315052 | Background | Hou XW, Wang Y, Pan CW. Metabolomics in Age-Related Macular Degeneration: A Systematic Review. Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):13. doi: 10.1167/iovs.61.14.13. |
| D009930 |
| Organic Chemicals |
| D007651 | Keto Acids |